Novartis Portfolio Shifts as Generic Competition Rises
The pharmaceutical company sees legacy revenue fall as it pivots capital toward newer immunology and oncology assets.
Updated on Oct. 30, 2026 in Healthcare
Live Poll
Is it concerning when a company's revenue relies on a few drugs facing future patent expiration?
Novartis reported $14.522 billion in net sales for Q3 2026, a 4% increase driven by double-digit growth in its key oncology and immunology products. The quarterly performance reflects a transition away from older blockbusters as the company manages significant portfolio changes.
Why it matters
Generic competition is rapidly eroding legacy revenue, forcing a reliance on newer assets like Kisqali and Kesimpta to maintain momentum. This shift underscores the high operational stakes of patent life cycles and the capital-intensive nature of late-stage research pivots.
Net sales hit $14.522 billion in Q3 2026, supported by 37% growth in Kisqali to $1.821 billion and 21% growth in Kesimpta to $1.484 billion. These gains were partially offset by a 38% decline in Entresto sales to $1.165 billion due to generic competition.
The players
Novartis
A Switzerland-based global pharmaceutical manufacturer with a large-scale portfolio of oncology and immunology drugs.
The details
Sales growth was driven by a 14-percentage-point increase in volume, while generic competition and pricing pressure subtracted nine and one percentage points from overall growth, respectively. Novartis also recorded a $1.9 billion impairment charge following a failed clinical study for its del-desiran asset. The company is now reallocating resources toward its remibrutinib program, which showed superior relapse rates in trials against teriflunomide.
Timeline
Q3 2026: Financial results were recorded for the quarter ending September 30.
Q4 2026: Novartis plans to submit remibrutinib for U.S. regulatory approval.
Nov. 18-19, 2026: Management will discuss operational strategy at an investor event.
2031: Estimated U.S. patent expirations for current growth drivers Kisqali and Kesimpta.
Market Landscape
Novartis is navigating a familiar transition as legacy blockbusters lose exclusivity under U.S. Patent Act protections. This shift forces a recurring reliance on new research assets to fill looming revenue gaps in the company's long-term portfolio.
Operators should monitor how pharmaceutical giants reallocate research capital after high-value asset impairments. Pay close attention to the 2031 patent expiration window for major growth assets when evaluating long-term supply chain and partnership stability.
The takeaway
The sharp decline in legacy revenue highlights the risk of over-reliance on single products as generic competitors enter the market. Leaders should audit their own product portfolios to identify similar sunset periods that may require immediate reinvestment.
What happens next
Novartis management will host an investor event on November 18-19, 2026, to discuss company strategy.
Further reading
For broader trends on how pharmaceutical firms manage drug life cycles, visit the Healthcare section.
Source note: This article includes information reported by TokenPost.
Live Poll
Is it concerning when a company's revenue relies on a few drugs facing future patent expiration?
